Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 20/20 | 0.68 |
| ▸ | EGFR | P00533 | 7/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.68 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.57 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.57 |
| ▸ | FECH | P22830 | 1/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.45 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.45 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4492740 | 1.00 | ERBB2 (0.68) | ERBB2EGFRKCNH2ERBB3ERBB4 | |
| SCHEMBL4480616 | 0.86 | ERBB2 (0.72) | ERBB2EGFRKCNH2ERBB3ERBB4 | |
| SCHEMBL4484888 | 0.86 | ERBB2 (0.72) | ERBB2EGFRKCNH2ERBB3ERBB4 | |
| SCHEMBL4477486 | 0.86 | ERBB2 (0.66) | ERBB2EGFRKCNH2ERBB3ERBB4 | |
| SCHEMBL5569993 | 0.85 | ERBB2 (0.71) | ERBB2EGFRKCNH2ERBB3ERBB4 | |
| SCHEMBL4472217 | 0.85 | ERBB2 (0.73) | ERBB2EGFRKCNH2ERBB3ERBB4 | |
| SCHEMBL4478544 | 0.85 | ERBB2 (0.73) | ERBB2EGFRKCNH2ERBB3ERBB4 | |
| SCHEMBL4478475 | 0.84 | ERBB2 (0.72) | ERBB2EGFRKCNH2ERBB3ERBB4 | |
| SCHEMBL5634782 | 0.84 | ERBB2 (0.75) | ERBB2EGFRKCNH2ERBB3ERBB4 | |
| SCHEMBL5566476 | 0.84 | ERBB2 (0.82) | ERBB2EGFRKCNH2ERBB3ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625908-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-12-01 | — | — | US | disclosed |
| US-20070244136-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| EP-1685116-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005051923-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244136-A1 | Quinazoline Derivatives | ERBB2, ABL1, MKI67 | ERBB2 1/4885EGFR 10/4885KCNH2 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.